Gold dumps on vaccine news and strong U.S. data

Gold dumps on vaccine news and strong U.S. data

Ole Hansen

Head of Commodity Strategy

Summary:  In our latest gold update we highlighted the risk to precious metals from an ongoing flow of positive news related to Covid-19 vaccines. Yesterday's slump below support at $1850/oz has continued today thereby raising fresh investor concerns about the metals ability to move higher into a vaccine-led global recovery.


In our latest gold update we highlighted the risk to precious metals from an ongoing flow of positive news related to Covid-19 vaccines. Yesterday it slumped below support at $1850/oz thereby raising fresh investor concerns about the metals ability to move higher into a vaccine-led global recovery.

Earlier in the day the market had been spooked by news that the U.S. is gearing up for a vaccine roll out within weeks, an AstraZeneca vaccine that works better in small doses and can be stored at higher temperatures than those being produced by Pfizer and Moderna. What eventually took it lower was the dollars knee-jerk reaction higher in response to much stronger than expected U.S. PMI data. While the dollar later turned lower, the damage to gold had already been done with the break below support attracting long liquidation and short-selling signals from algos.

Gold trades below key support at $1850/oz with the next level of support being the 200-day moving average just below $1800/oz. A break back above $1850/oz and confirmed by a move above $1900/oz is now needed to end the current consolidation/correction phase.

Source: Saxo Group

The weakening sentiment can also be seen through the options market where the cost of a 25% delta Call with a three-month expiry over a similar put has fallen to 1%, the lowest since April 2019. Today sees the expiry of December COMEX gold options and before yesterday’s break below $1850/oz, the open interest on puts and calls from strikes $1850 down to $1800 stood above 35,000 lots (35 million ounces) and the mentioned break is likely to have attracted hedging activity from both camps.

Some additional uncertainty was removed late in the day when Trump without acknowledging defeat – which he never will -  finally instructed the General Services Administration to begin the formal transition planning.

Responding to these developments, investors pulled another 345k ounces from Exchange-traded fund investments. Thereby taking the total reduction since November 9, when the first vaccine news hit, to 2 million ounces. The aggregate open interest in COMEX gold futures meanwhile rose, a sign of increased short selling activity. 

Is it all over for gold some may now ask. We believe the answer is no but also acknowledge that gold and silver once again do what they do best, i.e. frustrate investors. While the hopefully successful rollout of vaccines next year will support growth and the stock market, we also see tailwinds for investment metals. The dollar is likely to weaken as investors look to emerging markets for better opportunities, not least if bond yields climb thereby strengthening the rotation to value from momentum. Analysts at the big banks predict that the dollar could fall 20% if widely available coronavirus jab leads to an economic rebound in 2021. This according to a recent article in the $FT called “Vaccine arrival expected to trigger dollar slump in 2021”.

With former Fed Chair Janet Yellen likely heading into government as Biden’s pick for Treasury secretary, the doves will fly, both in government and at the Federal Reserve. With this in mind we are likely to see more, not less stimulus over the coming months. Such actions may increase the risk of central banks overcompensating thereby reigniting the reflation trade. On that basis we do not see a major risk of rising real yields with a potential pick-up in nominal yields being driven by rising inflation expectations (breakeven).

    Disclaimer

    The Saxo Bank Group entities each provide execution-only service and access to Analysis permitting a person to view and/or use content available on or via the website is not intended to and does not change or expand on this. Such access and use are at all times subject to (i) The Terms of Use; (ii) Full Disclaimer; (iii) The Risk Warning; (iv) the Rules of Engagement and (v) Notices applying to Saxo News & Research and/or its content in addition (where relevant) to the terms governing the use of hyperlinks on the website of a member of the Saxo Bank Group by which access to Saxo News & Research is gained. Such content is therefore provided as no more than information. In particular no advice is intended to be provided or to be relied on as provided nor endorsed by any Saxo Bank Group entity; nor is it to be construed as solicitation or an incentive provided to subscribe for or sell or purchase any financial instrument. All trading or investments you make must be pursuant to your own unprompted and informed self-directed decision. As such no Saxo Bank Group entity will have or be liable for any losses that you may sustain as a result of any investment decision made in reliance on information which is available on Saxo News & Research or as a result of the use of the Saxo News & Research. Orders given and trades effected are deemed intended to be given or effected for the account of the customer with the Saxo Bank Group entity operating in the jurisdiction in which the customer resides and/or with whom the customer opened and maintains his/her trading account. Saxo News & Research does not contain (and should not be construed as containing) financial, investment, tax or trading advice or advice of any sort offered, recommended or endorsed by Saxo Bank Group and should not be construed as a record of our trading prices, or as an offer, incentive or solicitation for the subscription, sale or purchase in any financial instrument. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, would be considered as a marketing communication under relevant laws.

    Please read our disclaimers:
    - Notification on Non-Independent Investment Research (https://www.home.saxo/legal/niird/notification)
    - Full disclaimer (https://www.home.saxo/legal/disclaimer/saxo-disclaimer)
    - Full disclaimer (https://www.home.saxo/en-mena/legal/disclaimer/saxo-disclaimer)


    Due to coronavirus controls, we are not able to meet with clients in our reception at present, unless by appointment in exceptional circumstances. We remain at your service on the phone and email details below. Thank you for your understanding.

    Please expect very long waiting times on the line when calling us, we advise you to send us an email instead.

    Contact Saxo

    Select region

    UAE
    UAE

    Trade responsibly
    All trading carries risk. Read more. To help you understand the risks involved we have put together a series of Key Information Documents (KIDs) highlighting the risks and rewards related to each product. Read more

    Saxo Bank A/S is licensed by the Danish Financial Supervisory Authority and operates in the UAE under a representative office license issued by the Central bank of the UAE.

    The content and material made available on this website and the linked sites are provided by Saxo Bank A/S. It is the sole responsibility of the recipient to ascertain the terms of and comply with any local laws or regulation to which they are subject.

    The UAE Representative Office of Saxo Bank A/S markets the Saxo Bank A/S trading platform and the products offered by Saxo Bank A/S.